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Abstract
Background: Intermittent preventive treatment for malaria in children (IPTc) is a promising new intervention for the
prevention of malaria but its delivery is a challenge. We have evaluated the coverage of IPTc that can be achieved by two
different delivery systems in Ghana.
Methods: IPTc was delivered by volunteers in six villages (community-based arm) and by health workers at health centres or
at Expanded Programme on Immunisation outreach clinics (facility based) in another six communities. The villages were
selected randomly and drugs were administered in May, June, September and October 2006. The first dose of a three-dose
regimen of amodiaquine plus sulphadoxine-pyrimethamine was administered under supervision to 3–59 month-old
children (n=964) in the 12 study villages; doses for days 2 and 3 were given to parents/guardians to administer at home.
Results: The proportion of children who received at least the first dose of 3 or more courses of IPTc was slightly higher in
the community based arm (90.5% vs 86.6%; p=0.059). Completion of the three dose regimen was high and similar with
both delivery systems (91.6% and 91.7% respectively).
Conclusion: Seasonal IPTc delivered through community-based or facility-based systems can achieve a high coverage rate
with the support and supervision of the district health management team. However, in order to maximise the impact of
IPTc, both delivery systems may be needed in some settings.
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Introduction
Seasonal intermittent preventive treatment for malaria in
children (IPTc) is a promising new intervention for the prevention
of malaria in children. Seasonal IPTc is safe and can reduce the
burden ofmalariasubstantially incountriesof Sahelian WestAfrica.
Dicko and colleagues in Mali showed that two treatments with
suphadoxine-pyrimethamine (SP) given two months apart at the
height of the malaria transmission season reduced the incidence of
malaria by 40% in children 6 months to 10 years old [1]. Three
treatment courses of SP plus a single dose of artesunate given during
the high transmission season to children aged less than five years
reduced the incidence of malaria by 86% in Senegal [2]. Three
courses of SP given bimonthly reduced clinical malaria by 24% and
anaemia (Hb,8.0 g/dl) by 30%, and six courses of artesunate plus
amodiaquine (AQ) given monthly reduced clinical malaria by 69%
and anaemia by 45% in the Hohoe district of Ghana [3].
A recent study in Senegal showed that IPTc using SP + AQ
given for 3 days had the best protective efficacy compared to three
other drug regimens. The adjusted hazard ratio for the incidence
of malaria was 0.50 (95% CI 0.31,0.81) for SP (1 dose) +AQ given
for 3 days, 0.90 (95% CI 0.60, 1.36) for SP (1 dose) + AS given for
3 days 1.13 (95% CI 0.76, 1.67) and AQ+AS given for 3 days
when compared to SP +AS each given for one day [4].
Although IPTc with AQ and SP is safe and efficacious, there are
concerns over how it can be delivered in an effective and sustainable
way. In order to be effective, the delivery system must be accessible
to the maximum number of target children, the SP/AQ must be
offered to the correct children by the provider, and the correct
regimen must be adhered to by the carer of the child. In terms of
sustainability, the first consideration is whether it is possible to
achieve effective delivery through routine public sector delivery
systems. Delivery of IPTc during routine EPI/growth monitoring
clinic visits must, therefore, be considered as one possible delivery
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IPTc through this system may not reach the maximum target
numbers in Ghana and other countries of West Africa. Firstly, the
coverage of EPI vaccination islow inseveral countriesofWestAfrica
[5]. Secondly, in Ghana, immunisation and growth monitoring visits
are more frequent amongst those under one year old than in those
over one year (2004 Jasikan district annual report). It might be
possible to increase the effectiveness of delivery through EPI/growth
monitoring by using targeted health education campaigns to
encourage caretakers to attend. If perceptions of IPTc are positive,
then caretakers may be encouraged to use the clinics more regularly.
Conversely, it is also plausible that the increased workload on the
health services staff due to this integrated delivery of IPTc and
growth monitoring could lead to programme fatigue.
Another option is a community based, volunteer delivery
systems of the kind that has been used successfully for mass
treatment of onchocerciasis [6], lymphatic filariasis [7], schistoso-
miasis [8], and trachoma and to administer treatment for malaria
[9,10,11,12]. Due to disappointing coverage with Intermittent
Preventive Treatment for pregnant women (IPTp) in some
situations [5], there have been attempts to deliver IPTp through
a variety of community based systems [13,14,15]. These systems
have been successful in delivering IPTp to pregnant women but
there is current debate and conflicting evidence on their impact on
access to other antenatal services by pregnant women.
Ensuring that the correct amount of drugs are delivered to
targeted children at the most appropriate time of the year and
sustaining adherence to the treatment regimen through any
delivery system is a challenge. However, these challenges are not
insurmountable and different ways of delivering IPTc need to be
explored. In this paper we describe an evaluation of two different
approaches to the delivery of IPTc in Ghana.
Materials and Methods
The protocol of this trial and supporting CONSORT checklist
are available as supporting information see Checklist S1 and
Protocol S1.
Study area
The study took placeinthe Jasikan districtof Ghana from Mayto
October 2006. The Jasikan District is within the semi-equatorial
climatic zone and has an extended rainy season (April – November)
with peaks in May-July and September-October. The district has
two hospitals, 9 health centres, 17 reproductive and child health
static clinics, 3 private maternity homes and 2 private clinics. The
district also has 80 Expanded Programme on Immunisation (EPI)
outreach clinics. In children under the age of five years resident in
the study area in 2006 who were treated for clinical malaria the
day28PCRcorrectedadequateclinicalandparasitologicalcurerate
was 75% (95% CI 69,80) for SP (n=241) and 85% (95% CI 69,80)
for AS+AQ (n=241) (Kweku M et al in preparation).
Study design and conduct
The study had two arms; IPTc was delivered either at the
outpatient department of health centres and at EPI outreach
clinics [health facility-based IPTc] or by community volunteers
[community-based IPTc] (Figure 1). Sampling was carried out
in two stages.From a sampling frame of all villages in the district
with a static reproductive and child health facility (n=17), six
villages were randomly selected using a sampling interval of 3.
From this sample of 6 villages, 3 villages were allocated to the
facility based arm and 3 villages to the community based arm by
ballot. Similarly from a sampling frame of 80 villages that had
no static health facility, 6 villages were randomly selected using
a sampling interval of 13. From this sample of 6 villages, 3
villages were assigned to the facility based arm (IPTc was
delivered at outreach EPI clinics) and 3 to the community based
arm by ballot. The study villages were on average within 5
kilometres from the static health facility. None of the health
facilities were inaccessible during the study period.
Members of the district health management team and the
principal investigator (MK) explained the objectives of the study to
leaders of the study villages and obtained their consent for the trial.
All children aged 3–59 months (1039) resident in the 12 study
villages were then enumerated in May 2006. Children whose
parents gave written consent (964) were enrolled into the study after
a physical examination. Only three children who had a history of
drug allergy were excluded. An identification card (ID card) with a
unique ID number was issued to all enrolled children. The dates
when IPTc was to be administered and the dose required were
indicated on the ID card. Parents were advised to refer to the ID
cards for information on the dates of IPTc drug administration and
on whether they should go to the community-based volunteers or to
the health facility to receive the study drugs. A finger prick blood
sample for examination of malaria parasite was obtained at
enrolment and at the end of the six month observation period.
District Health Management Team (DHMT) staff distributed
drugs to the health centre staff and community-based volunteers
and supervised the administration of drugs to children in May,
June, September and October. In the facility-based arm, health
workers who were providing outpatient treatment for sick children
gave IPTc to the study children on the scheduled IPTc days and
EPI nurses administered IPTc during the monthly out-reach
vaccination and growth monitoring clinic. In the community
based arm, children were invited to a central point in the village
on the scheduled IPTc days once a month for four months and the
community based volunteers administered the IPTc. Children in
each arm received a three day regimen of AQ plus a single dose of
SP in May, June, September and October. The first dose of the
drug was administered under supervision by a health worker or by
a community-based volunteer. Subsequent doses were dispensed
by parents/guardians at home after training. Tablets of AQ
(150 mg) and (SP) (500 mg sulfadoxine/25 mg pyrimethamine)
were given as follows: J tablet of each drug to 3 to 5 month-old
infants, 1/2 tablet of each drug to 6 to 11 month-old infants, 3/4
of each tablet to children aged 12 to 23 months and 1 tablet of
each drug to those aged 24 months or more. Tablets were crushed
and mixed with water and sometimes sweetened with sugar. Drugs
were administered based on age not on exact weight. Five days
after administration of the first dose of IPTc, field workers visited a
randomly selected 20% sample of the children in every village to
ask about side effects of drugs, detect any left over medication and
to enquire about the use of bednets. The number of children
surveyed after each course of IPTc ranged from 73 to 91 in the
community based arm and from 68 to 85 in the facility-based arm.
Community volunteers received a payment of $10 and facility-based
staff a salary supplement of $10 every month for undertaking the
additional work required to deliver and monitor coverage of IPTc.
Further details of the economics of the two approaches to drug delivery
will be presented elsewhere (Conteh et al. in preparation).
Carers were asked to take their child to the nearest health
facility for examination and treatment if he or she developed any
adverse event or any illness. Malaria episodes in study children
were monitored through a passive surveillance system at the health
centres and hospitals within the study area for a period of six
months after the last dose of the first course of drug had been given
(May - October 2006). A finger prick blood sample was collected
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suggestive of malaria before treatment with AS + AQ. Axillary
temperature was measured using an electronic thermometer when
a child reported at the health facility.
Blood slides were read twice at a central laboratory to give a
definitive diagnosis. Laboratory assistants examined thick blood
films for parasitaemia. A sample was considered negative only
after 200 high power fields had been read. Parasite counts were
converted to parasites per micro liter (ml), assuming a white blood
cell count of 8000 leukocytes per ml of blood. If there was a
discrepancy in the findings in a slide between the two initial
technicians (positive or negative or a 50% or more difference in
parasite density) a third, more senior microscopist read the slide
and his reading was deemed to be the correct reading. A senior
microscopist from the Noguchi Memorial Institute of Medical
Research (NMIMR, Ghana) examined all the positive blood films
and a 20% random sample of negative blood slides for quality
control. Haemoglobin (Hb) concentration was measured using a
Hemocue H Photometer (Leo Diagnostics, Sweden) in children
who attended study health facilities for suspected malaria or
anaemia. Children with an Hb,8.0 g/dl received treatment for
anaemia with iron 12.5 mg and folic acid 50 mg tablets daily for 14
days and those with an Hb=,6.0 g/dl were referred for hospital
management.
Sample size
The number of villages required for the trial was based on the
following assumptions. It was assumed that coverage of IPTc in the
community-based armwouldbe 80%, that the coefficient of variation
in the IPTc coverage between villages would be 0.4 and that the
number of children per village wouldbe between 60 and 100 (average
80). On the basis of these assumptions a study with 12 clusters would
have 80% power to detect a relative difference in coverage between
groups of 35% at a 5% level of significance. It was also assumed that
the incidence of malaria in the study area before the intervention
would be 19 per 1000 child weeks and it was expected that there
would be a 42% reduction in the incidence of malaria post
intervention, that the coefficient of variation in the malaria incidence
between villages would be 0.4 and that the number of children per
village would be between 60 and 100 (average 80). On the basis of
these assumptions the study had 80% power to detect a relative
difference in incidence before and after the intervention of 42% at a
5% level of significance. The sample size was calculated using the
formula suggested by Smith & Morrow [16].
Analysis
The primary outcome of the trial was coverage with IPTc.
Acceptable coverage was defined as the proportion of children
Figure 1. Trial Profile.
doi:10.1371/journal.pone.0007256.g001
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Poor coverage was defined as the proportion of children who
received the first dose of two or less courses of IPTc. Secondary
outcomes were (1) adherence to treatment (2) the incidence of
clinical malaria, (3) the incidence of anaemia, (4) the prevalence of
malaria parasitaemia at the beginning and at the end of the rainy
season and (5) the incidence of adverse events. Adherence to the
IPTc regimen was classified as follows; highly adherent - took first
supervised dose of all 4 courses; moderately adherent - took first
supervised dose of three courses; poorly adherent - took the first
supervised dose of two or less courses. An episode P. falciparum
clinical malaria was defined as a history of fever during the past
72 hours or an observed temperature $37.5u C plus the presence
of peripheral parasitaemia of any density. High parasite density
malaria was defined as parasitaemia .7000 per ml in the presence
of a history fever during the past 72 hours or a temperature
$37.5u. Anaemia was defined as an Hb ,8.0 g/dl.
For the analysis of coverage of IPTc, an intention to treat
analysis was used in which all children who were enrolled and
received the first dose of IPTc course one were included in the
analysis. Statistical significance of the difference in the coverage of
IPTc between the two arms was tested using logistic regression
with robust standard errors to take in to account the cluster effects.
The secondary outcome of adherence was defined as the
proportion of children who received all three doses of each course
of IPTc in the 20% random sample of children who were visited at
home. Statistical significance of the differences in the adherence
between the groups was tested by chi
2test.
For the analysis of the effect of IPTc on the incidence of malaria
and anaemia, we calculated person time at risk from the date of
enrolment to date of the final cross sectional survey (6 months after
the start of intervention). In addition, if a child received an
antimalarial drug (AS+AQ) during the follow up period, we
subtracted 28 day post treatment period from the person time at
risk. To compare the effect of ITPc on the incidence of malaria
between the two arms of the study, we used the random effects
Poisson regression model and robust standard errors to allow for
intra-cluster correlation and to adjust for the effect of age, and bed
net use.
To compare the prevalence of malaria parasitaemia between
the two arms of the study, we used a logistic regression model to
adjust for the effect of clustering in the communities using robust
standard errors and for the effect of age, bednet use and the
number of IPTc courses administered. All statistical analysis was
done using STATA version 10. (Statacorp LP).
Ethics
The trial was approved by the ethics committees of the London
School of Hygiene & Tropical Medicine and of the Ghana Health
Service/Ministry of Health (GHS/MOH).The trial was registered
on the NIH clinical trials database as an amendment to the
number ClinicalTrials.gov NCT00119132.
Results
Background characteristics
At enrolment, children in the two study groups were similar in
regard to age, gender, anthropometric indices and malaria parasite
prevalence (Table 1). The number of children per cluster varied
but was well balanced between the two groups. It ranged from 40
to 98 children (mean 73.8) in villages where IPTc was given in the
community and from 38 to108 (mean 83.2) in villages where the
delivery of IPTc was facility-based.
There was no statistically significant difference in the proportion
of households who owned an insecticide treated net (ITN) between
villages in the community based arm and the facility based arm
(16.1 vs 19.2%; p=0.281). Similarly, there was no statistically
significant difference in the proportion of children who slept under
an ITN on the night before the survey between villages in the two
arms (11.4% vs 16.3% p=0.196).
Coverage with IPTc and adherence
The proportion of children who received 3 or more courses of
IPTc ranged from 72.9% to 94.8% in the community-based arm
and from 58.5% to 94.9% in the facility-based arm villages. The
mean coverage of IPTc was slightly higher in the community
based arm than in the facility-based arm (90.5 vs 86.6%; OR 1.47,
95% CI 0.63, 3.45) (Table 2). The proportion of children who
received all four courses of IPTc was also slightly higher in the
community based arm than in the facility-based arm (69.1 vs
65.5%; OR=1.18; 95% CI 0.62, 2.22). However these differences
in coverage of IPTc between the two arms were not statistically
significant.
Among the 650 children who were assessed for adherence to
IPTc doses, adherence to 3 doses of any course of IPTc ranged
from 85% to 100% and there was no difference in the adherence
to IPTc between the community based arm and the facility based
arm (Table 3).
Forty-four percent (110/248) parents/guardians interviewed
reported that they had used the ID card to determine the IPTc
drug administration day and where they should take their child to
receive treatment. Those who did not use the ID card gave the
following reasons: forgot 80 (32.3%), could not read 41(16.5%)
and did not understand what was written on the card 17 (6.9%).
After the administration of each course of IPTc, drug
distributors were asked to record on the ID card that the child
Table 1. Characteristics of study children at enrolment.
Characteristics
Community-
based arm
Facility-
based arm
Number of clusters (N) 66
Number of children enumerated in each study
arm n (%)
506 (48.7) 533 (51.3)
Number enrolled and received the first course
of IPTc n (%)
472 (93.1) 492 (92.3)
Age (in months) (mean, SD) 26.8 (15.89) 28.5 (16.54)
Sex n (%) male 264 (55.9) 246 (50.0)
Own bednet n (%) 112 (23.7) 139 (28.3)
Own ITN n (%) 76 (16.1) 94 (19. 1)
Slept under bednet last night n (%) 73 (15.5) 107 (21.74)
Slept under ITN last night n (%) 54 (11.4) 80 (16.3)
Proportion with temperature .=37.5uC n (%) 15 (3.2) 22 (4.5)
Malaria parasitaemia n (%) 51 (10.8) 61 (12.4)
Parasitaemia density.7000/ml n (%) 13 (2.8) 15 (3.1)
Underweight n (%) 118 (25.0) 123 (25.0)
Wasted n (%) 80 (16.9) 76 (15.5)
Stunted n (%) 35 (7.4) 49 (10.0)
BMI(mean, SE) 0.158 (0.026) 0.157
(0.025)
*Information obtained by interviewing parents/guardians of participants (use of
insecticide treated net or untreated net was distinguished).
doi:10.1371/journal.pone.0007256.t001
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percent (783/962) of ID cards were available to assess the record
of IPTc administration. Recording of IPTc drug administration on
ID cards was significantly higher for children who received IPTc
from community-based volunteers than for children who received
their IPTc from facility-based health workers (65% vs 39%
respectively) OR=2.90 (95% CI 1.57, 5.39 p,0.001).
Adverse events reported during the intervention period
No serious adverse event attributable to use of the study drugs
was recorded. One death occurred during the observation period.
This child became unwell before the fourth course of drug
administration. The probable cause of death ascertained by verbal
autopsy was a brain abscess.
Some children spat or vomited drugs immediately after their
administration due to the bitter taste of amodiaquine. In the
villages where IPTc distribution was community based, 3.5% (23/
650) of the children required a repeat dose of IPTc because of
vomiting compared to 2.5% (16/650) of children resident in
villages where IPTc distribution was facility-based.
One hundred and fifty-three of the 650 children (23.5%) visited
at home five days after administration of the first dose of IPTc
experienced at least one adverse event (Table 4). Common adverse
events noted by parents/guardians were vomiting/spitting drugs
(10.9%), drowsiness/general bodily weakness (8.0%). Other
adverse events noted were diarrhoea, body itch, abdominal pains,
common cold and a swollen face. The reported incidence of
adverse events fell with time and by the fourth course of drug
administration, less than 2% of children reported any adverse
event.
Incidence and prevalence of malaria and anaemia
The incidences of clinical malaria, microscopically confirmed
malaria of any parasite density and high parasite density were
lower in children in the facility based arm than in the community
based arm (Table 5). There was no statically significant difference
in the prevalence of parasitaemia between the two arms at the pre
implementation survey (10.2% vs 11.5%; OR 1.14, 95% CI 0.45,
2.87; p=0.78) or at the post implementation survey (7.5% vs
6.7%; OR 0.88, CI 0.26, 2.96; p=0.84).
Discussion
This study has shown that the coverage achieved for four
courses of IPTc was slightly higher employing a community-based
rather than a health facility-based delivery system. Both systems
achieved more than 60% coverage for all four courses and over
80% coverage for 3 or more courses. However, this required good
supervision and support from a District Health Management
Team and the study team.
In Ghana there are many communities without a static health
facility and, during the rainy season which is also the farming
season, approximately 25% of the population is not regularly
reached by EPI outreach clinics. Thus, although a facility-based
delivery system had a relatively high coverage (86.6%) in this
study, a substantial proportion of children would not have access
to if IPTc is delivered exclusively through the facility-based
approach.
It is likely that children who would not have access to IPTc
through the health facility-based delivery system would be those
living in the most inaccessible and deprived areas of the district
and would be those most at risk from malaria. Delivering IPTc
through the routine health system will require extra effort to reach
the deprived population and adequate supervision to ensure that
records are kept properly. In this area of Ghana where the study
was done, a combination of health facility-based and community-
based approach might be needed to maximise the impact of IPTc.
In other areas, different approaches may be appropriate to achieve
maximum coverage.
Although no serious adverse event attributable to the adminis-
trationof IPTc withAQ + SP was observed,a significant proportion
of caretakers (24%) reported mild adverse events within five days of
administration of IPTc. However, in the absence of a placebo group
it cannot be determined how many of these reported symptoms
were due to the drug and how many to associated minor illnesses.
Nevertheless, this is a concern if IPTc is to be rolled out on a
national scale. The main adverse events observed in this study were
bodily weaknessand drowsinessand vomiting ofdrugs (18.9%). The
reported incidence of adverse events fell over time after educating
caretakers to feed children with food containing sugar at the time of
Table 2. Comparison of coverage of IPTc between the two
arms.
Variables
Facility
based arm
Community
based arm
Number of clusters 6 6
Total number of children 492 472
Number of children who received at least
the first dose of $3 course of IPTc
426 (86.6)
$ 427 (90.5)
$
Odds ratio
* of receiving at least the first
dose of $3 course of IPTc
1.00 1.47 (0.63, 3.45)
£
*Clustering adjusted for using logistic regression with robust standard errors.
$Percentages; p=0.06.
£95% confidence limits.
doi:10.1371/journal.pone.0007256.t002
Table 3. Adherence to Intermittent Preventive Treatment Doses.
Outcome
Course 1
Community-
based N=91
n( % )
Course 1
Facility-
based
N=85
n( % )
Course 2
Community-
based N=90
n( % )
Course 2
Facility-
based
N=84
n( % )
Course 3
Community-
based N=73
n( % )
Course 3
Facility-
based
N=68
n( % )
Course 4
Community-
based N=80
n( % )
Course 4
Facility-
based
N=79
n( %
Received three doses 84 (92.3) 75 (88.2) 80 (88.9) 73 (86.9) 62 (84.9) 65 (95.6) 80 (100.0) 77 (97.5)
Received two doses 4 (4.4) 8 (9.4) 7 (7.8) 9 (10.7) 4 (5.5) 3 (4.4) - -
Received one dose or
none
3 (3.3) 2 (2.4) 3 (3.3) 2 (2.4) 7 (9.6) 0 (0.0) - 2 (2.5)
doi:10.1371/journal.pone.0007256.t003
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events and actions to mitigate them should be a priority for any
national IPTc programmes.
Most children (66/75) who reported at the health facility with a
history of fever received treatment for malaria but only 27% (20/
75) of the children had malaria parasitaemia. This high use of
antimalarial drugs is partly due to the current treatment guidelines
in Ghana that all children ,5 years of age who report at the health
facility with fever should be treated for malaria unless there is a
clear alternative cause for the fever.
The reasons for the lower incidence of malaria in the facility
based arm than in the community based arm are not clear. We
speculate that background incidence of malaria was higher in the
rural villages of the community based arm than the villages with a
static health facility. However, both arms of the study had rural
and semi-rural villages and the prevalence of fever and malaria
parasitaemia was not different between the groups at the baseline.
We conclude that seasonal IPTc using community-based or
facility-based delivery system can achieve high coverage in
children aged 3 to 59 months. However, a facility based approach
alone would not reach children living in areas without access to
formal health care system. Adverse events such as drowsiness,
general bodily weakness and vomiting of drugs may be concern for
using SP +AQ for IPTc. However, IPTc using four courses of
SP+AQ in areas with a prolonged seasonal transmission probably
can reduce the burden of malaria.
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Table 4. Reported symptoms during the five days post IPTc administration.
Symptom Course 1 N=177 n (%) Course 2 N=173 n (%) Course 3 N=141 n (%) Course 4 N=159 n (%) Total N=650 n (%)
Drowsiness/weakness 20 (11.3) 24 (13.9) 5 (3.5) 3 (1.9) 52 (8.0)
Vomited study drugs 19 (10.7) 26 (15.0) 17 (12.1) 9 (5.7) 71 (10.9)
Vomiting later but not drug 2 (1.1) 1 (0.6) 3 (2.1) 0 6 (0.9)
Diarrhoea 2 (1.1) 2(1.2) 1 (0.7) 0 5 (0.8)
Restless/body itch 5 (2.8) 1 (0.6) 0 0 6 (0.9)
Abdominal pains 1 (0.6) 0001 (0.2)
Common cold 3 (1.7) 0003 (0.5)
Swollen face 3 (1.7) 0 3 (2.1) 0 6 (0.9)
Convulsion 0 0 1 (0.7) 0 1 (0.2)
Palpitation 1 (0.6) 0 1 (0.7) 0 2 (0.3)
Yellowish urine 1 (0.6) 0001 (0.2)
Any adverse event 38 (21.5) 31 (17.9) 9 (6.4) 3 (1.9) 153 (23.5)
doi:10.1371/journal.pone.0007256.t004
Table 5. Comparison of incidence of malaria between the groups.
Outcome Community based arm (n=6) Facility based arm (n=6) Rate Ratio
*
P-
value
Events PYAR
Incidence/
1000PYAR Events PYAR
Incidence/
1000PYAR
Treated for malaria 53 133.0 398.5 13 136.5 95.2 0.24 (0.06, 0.99) 0.005
Confirmed malaria (any parasite density) 18 133.0 135.3 2 136.5 14.6 0.15 (0.02, 0.73) 0.022
Confirmed malaria (parasite density
.7000/ml)
13 133.0 97.7 1 136.5 7.3 0.08 (0.01, 0.86) 0.037
PYAR person years at risk.
*Rate ratio-adjusted for clustering effect, age, ITN use and gender.
doi:10.1371/journal.pone.0007256.t005
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